Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $35.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 22.39% year-over-year to $35.1 million in Q1 2026; TTM through Mar 2026 was $35.1 million, a 22.39% increase from a year earlier, with the FY2025 full-year figure at $34.1 million, up 12.94% from the prior year.
• Total Liabilities grew to $35.1 million in Q1 2026 per PLX's latest filing, from $34.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $75.9 million in Q1 2022 and bottomed at $28.6 million in Q2 2025.
• The 5-year median for Total Liabilities is $49.4 million (2023), against an average of $49.1 million.
• Across the five-year window, Total Liabilities rose 27.41% in 2024 and sank 54.6% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $66.4 million in 2022, then slipped by 23.43% to $50.9 million in 2023, then slumped by 40.62% to $30.2 million in 2024, then advanced by 12.94% to $34.1 million in 2025, then rose by 2.9% to $35.1 million in 2026.
• Per Business Quant, the three latest PLX Total Liabilities figures stand at $35.1 million (Q1 2026), $34.1 million (Q4 2025), and $29.4 million (Q3 2025).